IBDEI0GS ; ; 06-AUG-2013
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;AUG 06, 2013
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4,1340,0)
 ;;=ABDOMINAL PAIN^3^148
 ;;^UTILITY(U,$J,358.4,1341,0)
 ;;=CHEST WALL AND NECK^1^149
 ;;^UTILITY(U,$J,358.4,1342,0)
 ;;=THORACIC^2^149
 ;;^UTILITY(U,$J,358.4,1343,0)
 ;;=OTHER PROCEDURES^3^149
 ;;^UTILITY(U,$J,358.4,1344,0)
 ;;=NEW PATIENT^2^150
 ;;^UTILITY(U,$J,358.4,1345,0)
 ;;=ESTABLISHED PATIENT^1^150
 ;;^UTILITY(U,$J,358.4,1346,0)
 ;;=CONSULTATIONS^3^150
 ;;^UTILITY(U,$J,358.4,1347,0)
 ;;=POST-OP FOLLOW-UP^4^150
 ;;^UTILITY(U,$J,358.4,1348,0)
 ;;=MALE URETHRAL DILATION^3^151
 ;;^UTILITY(U,$J,358.4,1349,0)
 ;;=MISCELLANEOUS^4^151
 ;;^UTILITY(U,$J,358.4,1350,0)
 ;;=URODYNAMICS^5^151
 ;;^UTILITY(U,$J,358.4,1351,0)
 ;;=ZOLADEX^6^151
 ;;^UTILITY(U,$J,358.4,1352,0)
 ;;=CYSTOURETHROSCOPY^1^151
 ;;^UTILITY(U,$J,358.4,1353,0)
 ;;=FEMALE ONLY PROCEDURES^2^151
 ;;^UTILITY(U,$J,358.4,1354,0)
 ;;=UNLISTED UROLOGY PROCEDURES^7^151
 ;;^UTILITY(U,$J,358.4,1355,0)
 ;;=NEW PATIENT^2^152
 ;;^UTILITY(U,$J,358.4,1356,0)
 ;;=ESTABLISHED PATIENT^1^152
 ;;^UTILITY(U,$J,358.4,1357,0)
 ;;=CONSULTATIONS^3^152
 ;;^UTILITY(U,$J,358.4,1358,0)
 ;;=POST OP VISIT (GLOBAL)^4^152
 ;;^UTILITY(U,$J,358.4,1359,0)
 ;;=OTHER E&M SERVICES^5^152
 ;;^UTILITY(U,$J,358.4,1360,0)
 ;;=NEURO-UROLOGY^15^153
 ;;^UTILITY(U,$J,358.4,1361,0)
 ;;=BLADDER^1^153
 ;;^UTILITY(U,$J,358.4,1362,0)
 ;;=KIDNEY/URETER^8^153
 ;;^UTILITY(U,$J,358.4,1363,0)
 ;;=PENIS/EXTERNAL GENITALIA^16^153
 ;;^UTILITY(U,$J,358.4,1364,0)
 ;;=PROSTATE^18^153
 ;;^UTILITY(U,$J,358.4,1365,0)
 ;;=POST OP^17^153
 ;;^UTILITY(U,$J,358.4,1366,0)
 ;;=MISCELLANEOUS/SYMPTOMS^10^153
 ;;^UTILITY(U,$J,358.4,1367,0)
 ;;=MISC/CONDITIONS/STATES^9^153
 ;;^UTILITY(U,$J,358.4,1368,0)
 ;;=INFECTIONS-VENEREAL^7^153
 ;;^UTILITY(U,$J,358.4,1369,0)
 ;;=INFECTIONS-RENAL/URETER^6^153
 ;;^UTILITY(U,$J,358.4,1370,0)
 ;;=INFECTIONS-PROSTATE^5^153
 ;;^UTILITY(U,$J,358.4,1371,0)
 ;;=INFECTIONS-KIDNEY^4^153
 ;;^UTILITY(U,$J,358.4,1372,0)
 ;;=INFECTION-MISCELLANEOUS^3^153
 ;;^UTILITY(U,$J,358.4,1373,0)
 ;;=NEOPLASIA-BLADDER/URETHRA^11^153
 ;;^UTILITY(U,$J,358.4,1374,0)
 ;;=NEOPLASIA-PROSTATE^14^153
 ;;^UTILITY(U,$J,358.4,1375,0)
 ;;=NEOPLASIA-KIDNEY/URETER^13^153
 ;;^UTILITY(U,$J,358.4,1376,0)
 ;;=NEOPLASIA-EXTERNAL GENITALIA^12^153
 ;;^UTILITY(U,$J,358.4,1377,0)
 ;;=COMPLICATIONS^2^153
 ;;^UTILITY(U,$J,358.4,1378,0)
 ;;=NEW PATIENT^2^154
 ;;^UTILITY(U,$J,358.4,1379,0)
 ;;=ESTABLISHED PATIENT^1^154
 ;;^UTILITY(U,$J,358.4,1380,0)
 ;;=CONSULTATIONS^3^154
 ;;^UTILITY(U,$J,358.4,1381,0)
 ;;=RESPIRATORY^8^155
 ;;^UTILITY(U,$J,358.4,1382,0)
 ;;=CARDIOVASCULAR^4^155
 ;;^UTILITY(U,$J,358.4,1383,0)
 ;;=ABDOMINAL PAIN^2^155
 ;;^UTILITY(U,$J,358.4,1384,0)
 ;;=AFTERCARE POST SURGERY^3^155
 ;;^UTILITY(U,$J,358.4,1385,0)
 ;;=COMMON VASCULAR DX^1^155
 ;;^UTILITY(U,$J,358.4,1386,0)
 ;;=POST-OP COMPLICATIONS^7^155
 ;;^UTILITY(U,$J,358.4,1387,0)
 ;;=METASTATIC CANCER SITES^6^155
 ;;^UTILITY(U,$J,358.4,1388,0)
 ;;=GENERAL/SIGNS & SYMPTOMS^5^155
 ;;^UTILITY(U,$J,358.4,1389,0)
 ;;=DEBRIDEMENT^2^156
 ;;^UTILITY(U,$J,358.4,1390,0)
 ;;=I&D/ASPIRATION^3^156
 ;;^UTILITY(U,$J,358.4,1391,0)
 ;;=UNNA BOOT^4^156
 ;;^UTILITY(U,$J,358.4,1392,0)
 ;;=PEG TUBE^5^156
 ;;^UTILITY(U,$J,358.4,1393,0)
 ;;=WOUND VAC DRESSING^6^156
 ;;^UTILITY(U,$J,358.4,1394,0)
 ;;=VASCULAR PROCEDURES^1^156
